Literature DB >> 8437224

Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4.

S L Orloff1, M S Kennedy, A A Belperron, P J Maddon, J S McDougal.   

Abstract

Two assays for measuring inhibition of human immunodeficiency virus type 1 (HIV-1) infection by soluble CD4 (sCD4) are described. Experiments in which sCD4, HIV-1, and cell concentrations and sequence of combination, noninfectious/infectious particle ratio, and temperature were varied produced results that support the conclusion that sCD4 inhibits HIV-1 infection by two mechanisms: reversible blockage of receptor binding and irreversible inactivation of infectivity. Fresh isolates obtained from HIV-1-infected persons were tested in both assays and found to be more resistant to both mechanisms of sCD4-mediated inhibition than multiply passaged laboratory strains. Binding studies revealed similar affinities for sCD4 in detergent lysates of sensitive and resistant strains at both 4 and 37 degrees C. The avidity of intact virions for sCD4 was lower at 4 than at 37 degrees C, and in the presence of excess sCD4, less sCD4 was bound at 4 than at 37 degrees C. The avidity differences were similar for fresh isolates and laboratory strains. However, fresh isolates were more resistant to sCD4-induced shedding of envelope glycoprotein gp120 from intact virions than was the laboratory strain. Relative resistance to sCD4 by certain isolates does not represent a lower intrinsic affinity of their envelope for sCD4 or a lower capacity for sCD4 binding. Rather, an event that occurs after binding may account for the differences. This postbinding event or feature may be determined by regions of the envelope outside the CD4 binding site.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8437224      PMCID: PMC237516     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  A CD4 domain important for HIV-mediated syncytium formation lies outside the virus binding site.

Authors:  D Camerini; B Seed
Journal:  Cell       Date:  1990-03-09       Impact factor: 41.582

2.  Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4.

Authors:  J P Moore
Journal:  AIDS       Date:  1990-04       Impact factor: 4.177

3.  Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry.

Authors:  J S McDougal; J K Nicholson; G D Cross; S P Cort; M S Kennedy; A C Mawle
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

4.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.

Authors:  E S Daar; X L Li; T Moudgil; D D Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  Differences in the interaction of HIV-1 and HIV-2 with CD4.

Authors:  D J Looney; S Hayashi; M Nicklas; R R Redfield; S Broder; F Wong-Staal; H Mitsuya
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

6.  The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.

Authors:  J O Kahn; J D Allan; T L Hodges; L D Kaplan; C J Arri; H F Fitch; A E Izu; J Mordenti; J E Sherwin; J E Groopman
Journal:  Ann Intern Med       Date:  1990-02-15       Impact factor: 25.391

7.  A soluble form of CD4 (T4) protein inhibits AIDS virus infection.

Authors:  K C Deen; J S McDougal; R Inacker; G Folena-Wasserman; J Arthos; J Rosenberg; P J Maddon; R Axel; R W Sweet
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

8.  HIV requires multiple gp120 molecules for CD4-mediated infection.

Authors:  S P Layne; M J Merges; M Dembo; J L Spouge; P L Nara
Journal:  Nature       Date:  1990-07-19       Impact factor: 49.962

9.  Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding.

Authors:  D Healey; L Dianda; J P Moore; J S McDougal; M J Moore; P Estess; D Buck; P D Kwong; P C Beverley; Q J Sattentau
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

10.  Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial.

Authors:  R T Schooley; T C Merigan; P Gaut; M S Hirsch; M Holodniy; T Flynn; S Liu; R E Byington; S Henochowicz; E Gubish
Journal:  Ann Intern Med       Date:  1990-02-15       Impact factor: 25.391

View more
  55 in total

1.  Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography.

Authors:  Tommi A White; Alberto Bartesaghi; Mario J Borgnia; M Jason V de la Cruz; Rachna Nandwani; James A Hoxie; Julian W Bess; Jeffrey D Lifson; Jacqueline L S Milne; Sriram Subramaniam
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Authors:  Bimal K Chakrabarti; Marie Pancera; Sanjay Phogat; Sijy O'Dell; Krisha McKee; Javier Guenaga; James Robinson; John Mascola; Richard T Wyatt
Journal:  AIDS Res Hum Retroviruses       Date:  2011-01-19       Impact factor: 2.205

3.  Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events.

Authors:  B J Doranz; S S Baik; R W Doms
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

4.  Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.

Authors:  Jonathan Toma; Steven P Weinheimer; Eric Stawiski; Jeannette M Whitcomb; Stanley T Lewis; Christos J Petropoulos; Wei Huang
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

Review 5.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

6.  Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.

Authors:  W A O'Brien; S H Mao; Y Cao; J P Moore
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

7.  Viral multiplicity of attachment and its implications for human immunodeficiency virus therapies.

Authors:  J L Spouge
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules.

Authors:  M C Gauduin; G P Allaway; P J Maddon; C F Barbas; D R Burton; R A Koup
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain.

Authors:  Aemro Kassa; Navid Madani; Arne Schön; Hillel Haim; Andrés Finzi; Shi-Hua Xiang; Liping Wang; Amy Princiotto; Marie Pancera; Joel Courter; Amos B Smith; Ernesto Freire; Peter D Kwong; Joseph Sodroski
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

10.  Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes.

Authors:  A D Badley; J A McElhinny; P J Leibson; D H Lynch; M R Alderson; C V Paya
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.